[1] Takahashi N, Fujibayashi Y, Yonekura Y, et al. Copper62 ATSM as a hypoxic tissue tracer in myocardial ischemia[J]. Ann Nucl Med, 2001, 15:293-296.
[2] Koch CJ and Evans SM. Non-invasive PET and SPECT imag-ing of tissue hypoxia using isotopically labeled 2-nitroimi-dazoles[J]. Adv Exp Med Biol, 2003, 510:285-292.
[3] Imahashi K, Morishita K, Kusuoka H, et al. Kinetics of a pu-tative hypoxic tracer, 99mTc-HL91, in normoxic, hypoxic,is-chemic, and stunned myocardium[J]. J Nucl Med,2000, 41:1102-1107.
[4] Kaneta T, Takai Y, Kagaya Y, et al. Imaging of ischemic but viable myocardium using a new F-labeled 2-nitroimidazole analog, F-FRP170[J]. J Nucl Med, 2002, 43:109-116.
[5] Yue X and Tomanek RJ. Effects of VEGF (165)and VEGF (121) on vasculogenesis and angiogenesis in cultured embryonic quail hearts[J]. Am J Physiol Heart Circ Physiol,2001, 280:2240-2247.
[6] Tham E, Wang J, Piehl F, et al. Up regulation of VEGF-A without angiogenesis in a mouse model of dilated cardiomyopathy caused by mitochondrial dysfunction[J]. J Histochem Cytochem, 2002, 50:935-944.
[7] El-Omar MM, Lord R, Draper NJ, et al. Role of nitric oxide in post hypoxic contractile dysfunction of diabetic cardiomyopathy[J]. Eur J Heart Fail, 2003, 5:229-239.
[8] Patt M, Sorger D, Scheunemann M, Adduct of 2-[18F] FDG and 2-nitroimidazole as a putative radiotracer for the detection of hypoxia with PET:synthesis, in vitro-and in vivo-characterization[J]. Appl Radiat Isot, 2002, 57:705-712.
[9] Josse O, Labar D, Georges B, et al. Synthesis-of[18F] la beled EF3[2-(2-nitroimidazol-1-yl)-N-(3, 3, 3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia[J]. Bioorg Med Chem, 2001, 9:665-675.
[10] Koch CJ and Evans SM. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles[J]. Adv Exp Med Biol, 2003, 510:285-292.
[11] Hoffend J, Linke G, Mohammed A, et al. 99mTcO (BATNI), a novel nitroimidazole tracer:in vivo uptake studies in alchemic myocardium[J].Eur J Nucl Med Mol Imag,2003, 30:494-501.
[12] Johnson LL, Schofield L, Donahay T, et al. Myocardial uptake of a (99m)Tc-nitroheterocycle in a swine model of occlusion and reperfusion[J]. J Nucl Med, 2000, 41:1237-1243.
[13] Su ZF, Ballinger JR, Rauth AM, et al. A novel aminedioxide chelator for technetium-99m:synthesis and evaluation of 2-nitroimidazole-containing analogues as markers for hypoxic cells[J]. Bioconjug Chem, 2000, 11:652-663.
[14] Ng C, Sinusas A, Zaret B, et al. Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS181321), as a tracer for myocardial hypoxia[J]. Circulation, 1995, 92:1261-1268.
[15] Shi CQ, Sinusas AJ, Dione DP, et al. Technetium-99m-nitroimidazole (BMS181321):A positive imaging agent for detecting myocardial ischemia[J]. J Nucl Med, 1995, 36:1078-1086.
[16] Melo T, Duncan J, Ballinger JR, et al. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in rumors[J]. J Nucl Med, 2000, 41:169-176.
[17] Suzuki T, Nakamura K, Kawase T, et al. Biodistribution of hypoxic marker, 99mTc-HL91[J]. Kaku Igaku, 2001, 38:333-341.
[18] Okada RD, Johnson G, Nguyen KN, et al. HL-91-techentium-99m:a new marker of viability in ischemic myocardium[J]. J Nucl Cardiol, 1999, 6:306-315.
[19] Fujibayashi Y, Cutler CS, Anderson CJ, et al. Comparative studies of Cu-64-ATSM and C-11-acetate in a acute myocardial infarction model:ex vivo imaging of hypoxia in rats[J]. Nucl Med Biol, 1999, 26:117-121.
[20] Watanabe Y, Kusuoka H, Fukuchi K, et al. Contribution of hypoxia to the development of cardiomyopathy in hamsters[J]. Cardiovasc Res. 1997. 35:217-222.